Differential cellular internalization of anti-CD19 and -CD22 immunotoxins results in different cytotoxic activity.
about
Identification and characterization of fully human anti-CD22 monoclonal antibodies.Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trialFusogenics: a recombinant immunotoxin-based screening platform to select internalizing tumor-specific antibody fragments.Epitope mapping and key amino acid identification of anti-CD22 immunotoxin CAT-8015 using hybrid β-lactamase displayIn vivo targeting of B-cell lymphoma with glycan ligands of CD22.Production of unique immunotoxin cancer therapeutics in algal chloroplastsLiposomes modified by carbohydrate ligands can target B cells for the treatment of B-cell lymphomas.Incorporation of a hinge domain improves the expansion of chimeric antigen receptor T cells.Convergent potency of internalized gelonin immunotoxins across varied cell lines, antigens, and targeting moietiesRecombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes.Anti-CD22 antibody targeting of pH-responsive micelles enhances small interfering RNA delivery and gene silencing in lymphoma cellsImmunotoxin targeting glypican-3 regresses liver cancer via dual inhibition of Wnt signalling and protein synthesis.Whole-genome RNAi screen highlights components of the endoplasmic reticulum/Golgi as a source of resistance to immunotoxin-mediated cytotoxicityA guide to taming a toxin--recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer.Cloning and Expression of CD19, a Human B-Cell Marker in NIH-3T3 Cell Line.Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotoxTreatment of hematologic malignancies with immunotoxins and antibody-drug conjugates.Emerging pharmacotherapies for adult patients with acute lymphoblastic leukemia.Rationally designed chemokine-based toxin targeting the viral G protein-coupled receptor US28 potently inhibits cytomegalovirus infection in vivo.Immunotoxin resistance via reversible methylation of the DPH4 promoter is a unique survival strategy.Targeting malignant B cells with an immunotoxin against ROR1A vaccine directed to B cells and produced by cell-free protein synthesis generates potent antilymphoma immunityRituximab mediates loss of CD19 on B cells in the absence of cell death.Immunoconjugates in the management of hairy cell leukemia.Monoclonal antibody-based therapies: a new dawn in the treatment of acute lymphoblastic leukemiaThe nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity.Chimeric Antigen Receptor T Cell Therapy in Hematology.A modified form of diphthamide causes immunotoxin resistance in a lymphoma cell line with a deletion of the WDR85 gene.Antibody-based therapeutics for the treatment of human B cell malignanciesLinked-in: design and efficacy of antibody drug conjugates in oncologyImmunotoxins: the role of the toxin.Methylation of the DPH1 promoter causes immunotoxin resistance in acute lymphoblastic leukemia cell line KOPN-8.Genetic alteration of a bispecific ligand-directed toxin targeting human CD19 and CD22 receptors resulting in improved efficacy against systemic B cell malignancy.Novel CD7-specific nanobody-based immunotoxins potently enhanced apoptosis of CD7-positive malignant cells.Siglecs as targets for therapy in immune-cell-mediated disease.Acetazolamide Serves as Selective Delivery Vehicle for Dipeptide-Linked Drugs to Renal Cell CarcinomaImmunotoxins for leukemia.Class A β-lactamases as versatile scaffolds to create hybrid enzymes: applications from basic research to medicine.Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells.Targeted liposomal drug delivery systems for the treatment of B cell malignancies.
P2860
Q33523255-049D7749-557B-48D6-ACCD-215FACCA18BBQ33732575-CF3753A4-6573-4AA3-94EA-A6EBA9595247Q33763294-C944FC64-CFE2-4627-81D8-5C87DCD0E603Q33772436-62092BFE-36BB-49FB-8F33-6EC48560162CQ33931886-39228157-708B-4713-814E-337E93D62505Q34034756-90767926-B7B8-4197-9A45-8B2A42CAA1BEQ34470480-B6E6F1C9-C0A7-46C5-AC8E-E60567E75022Q34553167-55406909-656E-468F-89CC-BA2CA8FBAD21Q34575951-0D624015-48BB-4351-B89C-2524410314DEQ34804520-70422480-915B-4A12-9F53-BD1087E5306DQ35144394-840291B3-9551-49A6-8DD6-284FD18363C0Q35170403-4AB4C5AA-39D0-4024-AA76-4FA10497D382Q35189855-192E6DC1-1A8E-4527-8E09-FA59EFAAEAE0Q35230663-A47355CD-7081-4714-9E5D-709CEF22C014Q35307091-8C1407BB-1299-4F05-AA52-01DEA0B305E4Q35446035-E57367D6-A2F1-427B-9B13-8F541D8B8002Q35446333-6D573FFD-2ABC-48B8-A9EF-2FCA67AA64EFQ35740894-EDE2E919-E1C2-42AF-B72E-ECECF88B6A34Q35845907-CBCB0175-4320-4CED-BCC2-95FB2A1C7DB8Q35935802-5970D266-D170-4336-A477-ADB49634555FQ35969887-B4880AEC-130C-4B95-A85C-5A54215B7C77Q36221727-2C8F1AC6-F4F9-441E-851C-8011BA4E75E0Q36252683-7BA17962-C9FF-4152-A9FA-ED094BF77270Q36328016-B73957A8-D178-40E5-8E2B-CFA8BF18C428Q36339717-C5B6F0C6-66C6-4C36-8E20-727B5C8B9E83Q36408432-6623B5EE-E6D1-432A-80CD-D9C2017EC2E8Q36722700-BEA60324-25C2-49A2-A313-A1401B4040E8Q36796947-E99A7C71-6932-4FCA-9C38-F020739A121CQ36907540-3840BE60-EBC7-46B6-AE71-67C8AEA44E36Q37029370-2854038C-F4EC-4B69-B1BA-70F432D5CE3FQ37139525-57B2CB00-48A3-4E7E-A4A8-9E8321F7B616Q37282218-C3598E5C-1C57-443D-A711-2BB1BEF9C27EQ37334787-A3F62BDA-E55A-423F-98F7-3A2E45412BE8Q37376200-7D2E9A1F-7BF5-447C-87F1-0E6C88B8FD1CQ37440061-85141228-570A-4C82-857F-884778BF600CQ37559487-500B3B1D-F1FF-40A5-A632-76AA05B05A14Q37709336-8E75D44D-C50A-4662-992A-25154B9583C1Q38143097-FE91077A-65BF-4177-AFD8-A76511AFE2B7Q38170500-211EAF90-ADB6-4F2A-B75C-BD1CBF7CA476Q38179032-146EB6B3-4640-4F9C-AEEE-C782CA9B774F
P2860
Differential cellular internalization of anti-CD19 and -CD22 immunotoxins results in different cytotoxic activity.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Differential cellular internal ...... different cytotoxic activity.
@en
type
label
Differential cellular internal ...... different cytotoxic activity.
@en
prefLabel
Differential cellular internal ...... different cytotoxic activity.
@en
P2093
P2860
P1433
P1476
Differential cellular internal ...... different cytotoxic activity.
@en
P2093
David J Fitzgerald
Ira Pastan
Richard Beers
P2860
P304
P356
10.1158/0008-5472.CAN-08-0461
P407
P577
2008-08-01T00:00:00Z